Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

New England Journal of Medicine

Volumn 335, Issue 26, 1996, Pages 1950-1955

  Alberts, David S ^a,l   Liu, P Y ^b   Hannigan, Edward V ^c   O'Toole, Robert ^d   Williams, Stephen D ^e,f   Young, James A ^g,h   Franklin, Ernest W ⁱ   Clarke Pearson, Daniel L ^e   Malviya, Vinay K ^j   DuBeshter, Brent ^e,k   Adelson, Mark D ^e   Hoskins, William J ^e  

^a UNIVERSITY OF ARIZONA   (United States)

^b SW Oncology Group Statistical Center ^*  (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e Gynecologic Oncology Group   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Eastern Cooperative Oncology Group   (United States)

^h Cancer Care Associates   (United States)

ⁱ Atlanta Reg Comm Clin Oncol P   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

^k UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^l Southwest Oncology Group   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; HEARING LOSS; HUMAN; INTERMETHOD COMPARISON; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; NEUROMUSCULAR DISEASE; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TINNITUS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HEARING DISORDERS; HUMANS; INFUSIONS, INTRAVENOUS; INFUSIONS, PARENTERAL; LEUKOPENIA; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0346423733     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199612263352603     Document Type: Article

References (15)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30. [Erratum, CA Cancer J Clin 1995;45:127-8.]
2. Miller BA, Ries LAG, Hankey BF, et al., eds. SEER cancer statistics review: 1973-1990. Bethesda, Md.: National Cancer Institute, 1993. (NIH publication no. 93-2789.)
3. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5: 1157-68.
4. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-65.
5. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-11.
6. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982;97:845-51.
7. Goel R, Cleary SM, Horton C, et al. Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst 1989;81: 1552-60.
8. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 1987;5:1607-12.
9. Kirmani S, Lucas WE, Kim S, et al. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol 1991;9:649-57.
10. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
11. Piccart MJ, Speyer JL, Markman M, et al. Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol 1985;12:Suppl 4:90-6.
12. Markman M. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986;13:219-42.
13. Idem. Intraperitoneal chemotherapy for gynecologic malignancies. In: Deppe G, ed. Chemotherapy of gynecologic cancer. 2nd ed. New York: Alan R. Liss, 1990:375-90.
14. Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW, McVie JG. Direct diffusion of cis-diamminedichloroplatinurn(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-4.
15. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.